Insider Buying: Dyne Therapeutics (NASDAQ:DYN) Director Purchases 2,000 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner bought 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were acquired at an average price of $18.21 per share, with a total value of $36,420.00. Following the purchase, the director owned 20,000 shares of the company’s stock, valued at $364,200. The trade was a 11.11% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Dyne Therapeutics Stock Performance

NASDAQ DYN traded up $0.40 on Thursday, reaching $18.56. The stock had a trading volume of 1,270,310 shares, compared to its average volume of 1,988,207. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. Dyne Therapeutics, Inc. has a 12-month low of $8.06 and a 12-month high of $25.00. The business’s 50-day moving average price is $18.27 and its 200 day moving average price is $18.31. The stock has a market cap of $3.07 billion, a P/E ratio of -5.76 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period in the previous year, the firm posted ($1.05) earnings per share. As a group, equities analysts expect that Dyne Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Institutional Trading of Dyne Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in DYN. T. Rowe Price Investment Management Inc. lifted its position in shares of Dyne Therapeutics by 523.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after acquiring an additional 14,727,667 shares in the last quarter. Orbis Allan Gray Ltd purchased a new stake in shares of Dyne Therapeutics in the fourth quarter valued at $93,926,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Dyne Therapeutics in the second quarter valued at $30,378,000. Perceptive Advisors LLC lifted its position in shares of Dyne Therapeutics by 543.7% in the fourth quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock valued at $68,048,000 after acquiring an additional 2,938,500 shares in the last quarter. Finally, Marshall Wace LLP lifted its position in shares of Dyne Therapeutics by 572.9% in the third quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock valued at $38,119,000 after acquiring an additional 2,565,570 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on DYN. Chardan Capital reiterated a “buy” rating and issued a $38.00 price objective on shares of Dyne Therapeutics in a research note on Monday, March 9th. HC Wainwright lowered their target price on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Wall Street Zen raised Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Finally, Morgan Stanley lowered their target price on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.